An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7110-7120

  Ara, Mst Naznin ^a   Matsuda, Takashi ^a   Hyodo, Mamoru ^a   Sakurai, Yu ^a   Hatakeyama, Hiroto ^a   Ohga, Noritaka ^a   Hida, Kyoko ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Aptamer liposomes; Endocytosis; Intracellular uptake; Targeted delivery; Tumor endothelial cells

Indexed keywords

ENDOTHELIAL CELLS; ENZYME INHIBITION; LIPOSOMES; MAMMALS; MOLECULAR BIOLOGY;

APTAMER-LIPOSOMES; CONFOCAL LASER SCANNING MICROSCOPY; ENDOCYTOSIS; INTRACELLULAR UPTAKE; MALDI-TOF MASS SPECTROSCOPY; PHOSPHOETHANOLAMINE; RENAL CELL CARCINOMA; TARGETED DELIVERY;

TUMORS;

APTAMER; CLATHRIN; LIPOSOME; MACROGOL 2000; NANOCARRIER; PHOSPHOETHANOLAMINE; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); DRUG CARRIER; LIGAND; MACROGOL DERIVATIVE; NANOMATERIAL; PHOSPHATIDYLETHANOLAMINE;

ANIMAL CELL; ARTICLE; CONFOCAL LASER MICROSCOPY; DRUG CONJUGATION; DRUG UPTAKE; ENDOCYTOSIS; ENDOSOME; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPECTROFLUOROMETRY; TARGET CELL; TUMOR CELL; TUMOR VASCULARIZATION; ULTRAVIOLET SPECTROSCOPY; ANIMAL; CELL CULTURE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PROCEDURES; TUMOR CELL LINE;

MUS;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELLS, CULTURED; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMANS; LIGANDS; LIPOSOMES; MICE; MICROSCOPY, CONFOCAL; NANOSTRUCTURES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS;

EID: 84902116608     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.087     Document Type: Article

References (45)

1. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarrier as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
2. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5:147-159.
3. Gupta A.K., Naregalkar R.R., Vaidya V.D., Gupta M. Recent advances on surface engineering of magnetic iron oxide nano-particles and their biomedical applications. Nanomedicine 2007, 2:23-39.
4. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
5. Lammers T., Aime S., Hennink W.E., Storm G., Kiessling F. Acc Chem Res 2011, 44:1029-1038.
6. Ellington A.D., Szostak J.W. Invitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
7. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment, RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
8. Shangguan D., Li Y., Tang Z., Cao Z.C., Chen H.W., Mallikaratchy P., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103:11838-11843.
9. Morris K.N., Jensen K.B., Julin C.M., Weil M., Gold L. High affinity ligands from invitro selection, complex targets. Proc Natl Acad Sci U S A 1998, 95:2902-2907.
10. Bunka D.H., Stockley P.G. Aptamers come of age - at last. Nat Rev Microbiol 2006, 4:588-596.
11. Liss M., Petersen B., Wolf H., Prohaska E. An aptamer-based quartz crystal protein biosensor. Anal Chem 2002, 74:4488-4495.
12. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010, 9:537-550.
13. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2-Fluropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). JBiol Chem 1998, 273:20556-20567.
14. Ni X., Castanares M., Mukherjee A., Lupoid S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011, 18:4206-4214.
15. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. JMol Biol 1965, 13:238-252.
16. Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev 2000, 43:197-205.
17. Maurer N., Fenske D., Cullis P.R. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001, 1:1-25.
18. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
19. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006, 1:297-315.
20. Willis M.C., Collins B., Zhang T., Green L.S., Sebesta D.P., Bell C., et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 1998, 9:573-582.
21. Cao Z., Tong R., Mishra A., Xu W., Wong G.C.L., Cheng J., et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed 2009, 48:6494-6498.
22. Kang H., O'Donoghue M.B., Liu H., Tan W. Aliposome-based nanostructure for aptamer directed delivery. Chem Commun 2010, 46:249-251.
23. Zhou J., Rossi J.J. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011, 21:1-10.
24. Xing H., Tang L., Yang X., Hwang K., Wang W., Yin Q., et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells invitro and invivo. JMater Chem B 2013, 1:5288-5297.
25. Li L., Hou J., Liu X., Guo Y., Wu Y., Zhang L., et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 2014, 35:3840-3850.
26. Hatakeyama H., Akita H., Harashima H. Amultifunctional envelop type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011, 63:152-160.
27. Folkman J. Tumor angiogenesis: therapeutic implications. NEngl J Med 1971, 285:1182-1186.
28. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006, 6:449-458.
29. Weigelt B., Peterse J.L., van't Veer L.J. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602.
30. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
31. Ferrara N., Kerbel R.S. Angiogenesis as therapeutic target. Nature 2005, 438:967-974.
32. Hida K., Klagsbrun M. Anew perspective on tumor endothelial cells, unexpected chromosome and centrosome abnormalities. Cancer Res 2005, 65:2507-2510.
33. Hida K., Hida Y., Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99:459-466.
34. Akino T., Hida K., Hida Y., Tsuchiya K., Freedman D., Muraki C., et al. Cytogenic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009, 175:2657-2667.
35. Matusda K., Ohga N., Hida Y., Muraki C., Tsuchiya K., Kurosu T., et al. Isolated tumor endothelial cells maintain the specific character during long-term culture. Biochem Biophys Res Commun 2010, 394:947-954.
36. Suzuki Y., Ohga N., Morishita Y., Hida K., Miyazono K., Watabe T. BMP-9 induces proliferation of multiple types of endothelial cells invitro and invivo. JCell Sci 2010, 123:1684-1692.
37. Ara M.N., Hyodo M., Ohga N., Hida K., Harashima H. Development of a novel DNA aptamer ligand targeting to primary cultured tumor endothelial cells by a cell-based SELEX method. PLoS One 2012, 7:e50174.
38. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006, 58:32-45.
39. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging invivo. Adv Drug Deliv Rev 2013, 65:71-79.
40. Nallamouthu R., Wood G.C., Pattillo C.B., Scott R.C., Kiani M.F., Moore B.M., et al. Atumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and invitro evaluation. AAPS PharmSciTech 2006, 7:E32.
41. Khalil I.A., Kogure K., Futaki S., Harashima H. High density octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. JBiol Chem 2006, 281:3544-3551.
42. Bally M.B., Harvie P., Wong F.M., Kong S., Wassan E.K., Reimer D.L. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 1999, 38:291-315.
43. Lodish H., Berk A., Matsudaira P., Kaiser C.A., Krieger M., Scott M.P., et al. Molecular cell biology 2004, 618-655. WHFreeman, New York. 5th ed.
44. Biessen E.A., Vietsch H., Kuiper J., Bijsterbosch M.K., Berkel T.J. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 1998, 53:262-269.
45. Peiser L., Mukhopadhyay S., Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol 2002, 14:123-128.